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a b s t r a c t
Interferon gamma (IFNγ) has complex immunomodulatory and antiviral properties. While IFNγ is
detected in the airways in response to infection with the pneumovirus pathogen, pneumonia virus of
mice (PVM; Family Paramyxoviridae), its role in promoting disease has not been fully explored. Here, we
evaluate PVM infection in IFNγ/ mice. Although the IFNγ gene-deletion has no impact on weight loss,
survival or virus kinetics, expression of IFNβ, IFNλ2/3 and IFN-stimulated 2–50 oligoadenylate synthetases
was signiﬁcantly diminished compared to wild-type counterparts. Furthermore, PVM infection in
IFNγ/ mice promoted prominent inﬂammation, including eosinophil and neutrophil inﬁltration into
the airways and lung parenchyma, observed several days after peak virus titer. Potential mechanisms
include over-production of chemoattractant and eosinophil-active cytokines (CXCL1, CCL11, CCL3
and IL5) in PVM-infected IFNγ/ mice; likewise, IFNγ actively antagonized IL5-dependent eosinophil
survival ex vivo. Our results may have clinical implications for pneumovirus infection in individuals with
IFNγ signaling defects.
Published by Elsevier Inc.
Introduction
The human pneumovirus pathogen, respiratory syncytial virus
(RSV) is the leading cause of lower respiratory tract infection
among infants and children worldwide and has been recognized in
the elderly (Borchers et al., 2013; Walsh 2011). A virus of the
Family Paramyxoviridae, genus Pneumovirus, RSV is an enveloped
single-stranded RNA virus that replicates in human alveolar
macrophages and bronchial epithelial cells in vivo. While most
disease is mild to moderate in nature, some infants are at high risk
for severe disease, including those with bronchopulmonary dys-
plasia, immunodeﬁciency, premature birth and congenital heart
disease; monoclonal antibody prophylaxis is available for these
individuals (Shadman and Wald, 2011). Although not currently
available, research and development is ongoing toward a safe and
effective RSV vaccine (Rudraraju et al., 2013).
Pneumonia virus of mice (PVM) is a natural pathogen of rodent
species that is of the same virus Family and genus as RSV. PVM
undergoes robust replication in lung tissue, elicits a profound
inﬂammatory response, and replicates the clinical picture of
severe RSV infection in most inbred strains of mice (reviewed in
Bem et al. (2011), Rosenberg and Domachowske (2008) and Dyer
et al. (2012)). We have utilized the PVM infection model to explore
the critical role of the proinﬂammatory cytokines in eliciting
morbidity and mortality characteristic of severe RSV infection
(Bonville et al., 2003, 2004; Gabryszewski et al., 2011).
Interferon gamma (IFNγ) is a pleiotropic cytokine with complex
immunomodulatory and antiviral properties. The biology and
immunology of IFNγ (also known as Type II interferon) and its
unique receptor, IFNγR, have been the subject of several excellent
reviews (Schroeder et al., 2004; Durbin et al., 2013; Platanias
2005; Randall and Goodbourn, 2008; Schoenborn and Wilson,
2007; Akdis et al., 2011). Interestingly, IFNγ is not among the most
prominent mediators detected in human RSV disease; levels have
been reported in some (Fernandez et al., 2005; Garofalo et al.,
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/yviro
Virology
http://dx.doi.org/10.1016/j.virol.2014.07.039
0042-6822/Published by Elsevier Inc.
n Correspondence to: Inﬂammation Immunobiology Section, Laboratory of Aller-
gic Diseases, National Institute of Allergy and Infectious Diseases, National
Institutes of Health, Building 10, Room 11C215, 9000 Rockville Pike, Bethesda,
MD 20892, USA.
1 Current Address: Investigative Toxicology, Department of Non-Clinical Devel-
opment, UCB BioPharma, sprl, Chemin du Foriest, 1, B-1420 Braine-L’Alleud,
Belgium.
2 Current Address: University of Colorado Denver - Anschutz Medical Campus,
12801 E 17th Ave, Aurora, CO 80010, USA.
3 Current Address: American Association for the Advancement of Science
(AAAS), Annual Meeting Staff, 1200 New York Avenue NW, Washington, DC, USA.
Virology 468-470 (2014) 140–149
2004; Juntti et al., 2005) but not all (Tabarani et al., 2013) studies
of human infants infected with RSV. However, inbred mice have
been used to investigate the role of IFNγ in modulating RSV
disease. Among these studies, Culley et al. (2002) found that RSV
challenge of newborn mice results in delayed IFNγ responses when
compared to older mice, and that elevated levels of IFNγ resulting
from delayed priming were associated with protection from severe
disease. Similarly Lee et al. (2008) found that IFNγ present during
primary RSV challenge of neonatal mice was crucial to maintain
protection against development of airways hyperreactivity and
lung histopathology upon secondary RSV challenge. Likewise,
Empey et al. (2012) found that neonatal mice provided with
recombinant IFNγ responded to RSV challenge with accelerated
virus clearance in association with classical alveolar macrophage
activation.
The role of IFNγ in promoting pathology has also been exam-
ined to some extent in primary PVM infection. For example, our
group has shown that IFNγ is produced in response to primary
PVM infection, but at levels that did not correlate directly with
physical measures of lung dysfunction (Bonville et al., 2006). We
have also found that IFNγ was not required for generation of
adaptive immunity to PVM (Ellis et al. 2007). Just recently, Walsh
et al. (2014) reported that IFNγ supported inﬂammation-related
morbidity in PVM infection, although Frey et al. (2008) had
previously examined PVM-induced morbidity in mice devoid of
IFNγR, and found no differences between gene-deleted and wild
type mice. Of note, all of the aforementioned studies were carried
out using mice on the C57BL/6 background strain, shown by Anh
et al. (2006) to be a relatively resistant to PVM infection.
Given the importance of IFNγ in modulating immunity and
immunopathology in virus infection, we embarked here on a more
systematic evaluation of the impact of IFNγ gene-deletion on the
BALB/c background, a strain shown to be highly susceptible to PVM
infection (Anh et al., 2006). In addition to evaluating weight loss and
survival, virus kinetics, and histopathology, we have determined a
previously unanticipated role for IFNγ in regulating the expression of
both IFNβ and IFNλ2/3 (Donnelly and Kotenko, 2010).
Results and discussion
IFNγ gene-deletion has no impact on survival or virus replication
and clearance in response to PVM infection
IFNγ gene-deleted (IFNγ /) and wild-type BALB/c mice were
infected with pneumonia virus of mice (PVM strain J3666; 0.033 to
3.3 TCID50 units in 50 mL inoculation volumes). As shown, the IFNγ
gene-deletion had no impact on survival in response to PVM
infection at any inoculation tested (Fig. 1A), and no impact on
weight loss prior to the onset of mortality (Fig. 1B). Interestingly,
IFNγ does protect against lethal infection with murine cytomega-
lovirus (Pomeroy et al., 1998), dengue virus (Fagundes et al., 2011;
Costa et al., 2012) and murine gamma-herpesvirus (Lee et al.,
2009; Tsai et al., 2011). In contrast, IFNγ signaling has no dis-
cernible impact on survival in response to vesicular stomatitis
virus, Semliki forest virus, or inﬂuenza virus (Graham et al., 1993;
Huang et al., 1993; Muller et al., 1994; van den Broek et al., 1995).
Our ﬁndings with PVM infection are similar to those in the latter
group, and are also similar to those of Frey et al. (2008) who
examined PVM strain 15 in IFNγR / mice, which are on the
C57BL/6 background. Background strain can play a critical role in
determining the impact of IFNγ signaling in acute infection; (Tsai
et al., 2011) found C57BL/6 mice did not require IFNγ to control
murine gamma-herpesvirus infection, while the same infection in
BALB/c IFNγ / mice resulted in profound morbidity and mortality
(Tsai et al., 2011; Lee et al., 2009).
Based on these results, we focused on the responses of both
wild-type and IFNγ / mice to the minimal inoculum (0.033
TCID50/mouse in 50 μL inoculation volume) which generates a
survivable infection in BALB/c mice. Both wild-type and IFNγ /
mice that receive this inoculum undergo seroconversion to PVM
antigens (data not shown); as documented previously, IFNγ signal-
ing is not crucial for seroconversion and generation of anti-PVM
IgG1 (Ellis et al., 2007). IFNγ was detected in lung tissue homo-
genates of wild-type mice on days 6–10 of infection; as antici-
pated, no immunoreactive IFNγ was detected at any time point in
IFNγ gene-deleted mice (Fig. 1C). This response pattern was
paralleled by production of CXCL9/MIG, a T cell chemoattractant
whose expression is tightly regulated by IFNγ (Groom and Luster,
2011; Fig. 1D).
IFNγ gene-deletion also had no impact on virus replication and
clearance (Fig. 1E). Both wild-type and IFNγ gene-deleted mice
supported robust virus replication, with peak recovery at day
7 and diminished levels of virus detected thereafter. No virus was
detected at day 21 post-inoculation. No differences in virus
recovery were observed when comparing the wild-type and IFNγ
gene-deleted mice at any time points evaluated.
IFNγ gene-deletion results in diminished expression of IFNβ
and IFNλ2/3 in response to PVM infection
Immunoreactive IFNα was detected in the airways of PVM-
infected wild-type and IFNγ/ mice, with peak detected at day
7 of infection, correlating with peak virus recovery (Fig. 2A). Peak
expression of transcripts encoding IFNβ (Fig. 2B) and IFNλ2/3
(IL28A/B; Fig. 2C) was also detected at day 7 of infection in both
wild-type and IFNγ/ mice. Expression of IFNλ2/3 has been
detected previously in response to inﬂuenza virus infection
(Jewell et al., 2010) and to PVM infection (Heinze et al., 2011).
However, we show here that expression of transcripts encoding
both IFNβ and IFNλ2/3 is signiﬁcantly diminished (each 2–3 fold)
in IFNγ / mice when compared to their wild-type counterparts
(po0.001). We did detect immunoreactive IFNλ2/3 in both lung
homogenates and bronchoalveolar lavage (BAL) ﬂuid of IFNγ /
mice. However, high background levels in uninfected tissue and
BAL ﬂuid, similar to what was reported previously by Heinze et al.
(2011), precluded clear interpretation of these ﬁndings.
Expression of transcripts encoding IFNβ and IFNλ2/3 is also
signiﬁcantly diminished in PVM-infected type I interferon receptor
(IFNαβR /) gene-deleted mice (Fig. 2D and E, (Muller et al.,
1994)). Gene expression patterns have been documented for
PVM infection in IFNαβR / mice (Garvey et al., 2005); in addition
to diminished expression of numerous interferon-stimulated
genes (ISGs), we observed overexpression of eotaxin-2 (CCL24)
in mouse lung tissue in association with Th2-type pulmonary
histopathology. Parallel to these ﬁndings, we observe diminished
expression of 2–50 oligoadenylate synthetases (Oas)1g, 2, and 3 in
IFNγ / mice compared to their wild-type counterparts (Figs. 3A–
C); differential expression of Mx1 does not reach statistical
signiﬁcance (Fig. 3D).
While there is substantial “cross-talk” via which IFNγ alters
signaling initiated by IFNβ (and vice versa; reviewed in (Schroeder
et al., 2004)), it is not immediately clear how IFNγ might limit the
expression of IFNβ or IFNλ2/3 by more direct means. The promo-
ters of IFNβ and of the better-characterized IFNλ1 are both
regulated by the coordinate actions of transcription factors
NF-kB and interferon-regulated factors (IRFs)-3 and -7; although
not yet fully characterized, the highly homologous promoter
sequences of IFNλ2/3 share consensus binding sequences for these
factors (Thomson et al., 2009; Durbin et al., 2013). IFNγ signaling
may target one or both of these transcription factors, either
directly or indirectly. There is already at least one example of this,
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notably shown by Hu et al. (2006, 2009) who described
IFNγ-mediated suppression of transcription factors CREB and
AP-1, which ultimately leads to negative regulation of IL-10.
IFNγ gene-deletion promotes pulmonary inﬂammation
As shown in Fig. 4A, differential histopathology is observed at
day 10, several days after peak virus titer at day 7. Lesions are more
profound and diffuse in IFNγ/ than in wild-type mice (Fig. 4B
and C). Within the lung lesions in IFNγ / mice, we observe
alveolar exudates with granulocytes and cell debris accompanied
by a thickened interstitium. Compared to wild-type mice, IFNγ /
mice also exhibit more abundant perivascular and peribronchiolar
inﬁltrates, which also included granulocytes and mononuclear
cells (Fig. 4D and E). Granulocytes (both eosinophils and neutro-
phils) are prominent components of the bronchoalveolar lavage
ﬂuid of IFNγ / mice (Fig. 5A and B). Similarly, signiﬁcantly more
eosinophils (SiglecFþCD11c-) and neutrophils (Gr1þ) were detec-
ted in the lung tissue of IFNγ/ than wild-type mice at these
time points (Fig. 5C and D). In our recent work, we found
that eosinophils recruited to the airways in response to Aspergillus
fumigatus, but, interestingly, not in response to ovalbumin sensi-
tization and challenge, become activated and release the speciﬁc
granule protein, eosinophil peroxidase (EPX) in response to
Fig. 1. IFNγ gene-deletion has no impact on survival or virus replication and clearance in response to acute PVM infection. (A) Survival of IFNγ/ and wild-type BALB/c mice
inoculated on day 0 with 0.033 (diamonds; n¼8–9 mice per group), 0.33 (squares; n¼15–17 mice per group) or 3.3 TCID50 units (circles; n¼5 mice per group) of pneumonia
virus of mice (PVM strain J3666). (B) Body weight (g7sd, n¼5 mice per group until day 9) after inoculation with 0.33 TCID50 units PVM per mouse on day 0. (C) IFNγ and
(D) CXCL9/MIG are detected in lung tissue homogenates of wild-type, but not IFNγ-gene deleted mice inoculated with 0.033 TCID50 units PVM strain J3666 at day 0. (E) Virus
replication and clearance evaluated by dual-standard curve qRT-PCR (Gabryszewski et al., 2011) in whole lung tissue of IFNγ / and wild-type mice inoculated with 0.033
TCID50 units PVM strain J3666 at day 0; “a.” indicates peak virus titer at day 7, and “b.” indicates that virus can no longer be detected at day 21 post-inoculation; n¼6–10
mice per time point.
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subsequent challenge with PVM (Percopo et al., 2014). Here, in
IFNγ / mice, eosinophils are recruited to the airways in response
to PVM infection without prior priming, but they are not releasing
substantial amounts of EPX (Fig. 5E).
Sustained inﬂammation, notably, sustained eosinophilic inﬂam-
mation has been observed in the absence of IFNγ signaling in the
setting of allergic (Coyle et al., 1996; Zhao et al., 2008) and
infectious provocation (Wohlleben and Erb, 2004). Several groups
have explored the inﬂammatory response to RSV challenge in
IFNγ / mice, although there remains no clear consensus on these
results. Schwarze et al. (1999) documented substantial increases in
eosinophils (5-fold) and moderate increases in neutrophils in lung
tissue at 7 days after challenge with RSV in IFNγ/ compared to
wild-type BALB/c mice. Similarly, Boelen et al. (2002) reported
eosinophil recruitment and accumulation at the bronchioles in
response to RSV challenge of IFNγR/ mice (129SvEv background
strain). In contrast, Johnson et al. (2005) report that mice devoid of
IFNγR (also on the 129SvEv background) exhibit inﬂammatory
pathology that is indistinguishable from the wild-type, with
profound inﬂammation observed only in mice devoid of both type
I and type II IFN receptors or those devoid of the common
signaling pathway (ie…Stat1/ mice). As noted earlier with
respect to the study of gammaherpesvirus infections, the speciﬁc
background strain (Tsai et al., 2011), as well as age of the mice,
preparation and size of the virus inoculum may have substantial
impact on the results obtained.
Fig. 2. Differential expression of type I and type III interferons in response to PVM infection in wild-type and IFNγ/ mice. (A) Immunoreactive IFNα is detected in both
PVM-infected wild-type and IFNγ/ mice. (B) Differential expression of transcripts encoding IFNβ and (C) IFNλ2/3 in PVM-infected wild-type and IFNγ/ mice. Mice were
inoculated with 0.033 TCID50 units PVM strain J3666; n¼ 6–10 mice per time point. Shown are the means7SEM, ***po0.001, two-way ANOVA with Bonferroni’s multiple
comparisons test. (D) Differential expression of transcripts encoding IFNβ and (E) IFNλ2/3 in PVM-infected wild-type and IFNαβR/ mice; n¼5 mice per point.
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Differential expression of chemoattractant cytokines
In addition to the aforementioned mechanisms that have been
proposed to explain the more prominent inﬂammation observed
in IFNγ / mice, we detect overproduction of both eosinophil and
neutrophil chemoattractant cytokines in lung tissue of PVM-
infected mice. Speciﬁcally, we ﬁnd elevated levels of neutrophil
chemoattractants CXCL1 and CCL3, the eosinophil chemoattract
CCL11 and the eosinophil-active cytokine, IL-5 in lung tissue of
PVM-infected IFNγ / gene-deleted mice when compared to wild-
type counterparts (Fig. 6). IL-5 was also detected in BAL ﬂuid. Trace
levels of GM-CSF, another eosinophil-active growth and pro-
survival factor, were detected in lung homogenate and BAL ﬂuid
on day 7 only (data not shown). We have not deﬁned the source of
IL-5 in this setting, however it is intriguing to consider a role for
virus-induced epithelial cytokines activating innate lymphoid cells
(ILCs), notably IL-5-producing ILC2s in this setting [(Kumar et al.,
2014); similarly eosinophils themselves are a signiﬁcant source of
IL-5 (Rosenberg et al., 2013).
While the chemoattractant cytokines CXCL9, CXCL10, and
CXCL11 are regulated directly by IFNγ-mediated signaling
(reviewed in (Rauch et al., 2013; Groom and Luster, 2011)), other
chemoattractant cytokines are differentially regulated in the
absence of IFNγ or its receptor; these ﬁndings are often invoked
to explain differential leukocyte recruitment. For example, the
neutrophil chemoattractants CXCL1 and CCL3 were reported as
up-regulated in leukocytes recruited to the peritoneum of IFNγ /
mice infected with Trypanosoma cruzi (Aliberti et al., 2001). Like-
wise, overexpression of CCL11 was observed in draining lymph
nodes from IFNγ / mice immunized with interphotoreceptor
retinoid binding protein (IRBP) to model autoimmune uveitis (Su
et al., 2007). The speciﬁc connections and pathways linking IFNγ
signaling to these responses remain to be explored.
IFNγ antagonizes eosinophil survival
While Ochiai et al. (1999) demonstrated that peripheral eosi-
nophils express functional IFNγ receptors, the role of IFNγ in
promoting speciﬁc eosinophil functions remains unclear. Our
ﬁndings in Fig. 7A suggest that eosinophil survival may be limited
in the presence of IFNγ, and thus eosinophil survival will be
prolonged in IFNγ-deﬁcient PVM-infected mice. Speciﬁcally,
mouse eosinophils generated from bone marrow progenitors
(Dyer et al., 2008) were maintained in culture for an additional
8 days in the presence of IL-5, IFNγ, or IL-5 and IFNγ together, and
ongoing survival was monitored. We found that IFNγ, in contrast to
IL-5, does not support ongoing survival of eosinophils. Moreover,
IFNγ is not a neutral bystander, as it antagonized the pro-survival
impact of IL-5 at the concentrations shown. This antagonism is
wholly dependent on IFNγ signaling, as it was not observed in
mouse eosinophils generated from IFNγR/ progenitors (Fig. 7B).
Clearly, eosinophils in tissue subjected to elevated but physiologi-
cally relevant levels IFNγ (see Fig. 2C) may have reduced viability
relative to their counterparts in IFNγ / mice. Thus, while Letuve
et al. (2001) found that IFNγ prolonged survival of human
eosinophils ex vivo, our ﬁndings are more consistent with those
of de Bruin et al. (2010) who found that mice with chronically-
elevated levels of IFNγ were devoid of eosinophils, and that
eosinophilia and eosinophil hematopoiesis was suppressed in the
bone marrow of these mice even in the presence of elevated levels
of IL-5. While the mechanisms underlying these observations are
not yet clear, these observations may likewise contribute to our
understanding of the inﬂammatory responses in mice devoid of
IFNγ. Equally intriguing, there are no published reports on the
interactions of eosinophils with exogenous IFNλ. He et al. (2012)
reported that human intestinal eosinophils express IFNλ, and that
IFNλ is released in response to inﬂammatory stimuli. However, the
Fig. 3. Differential expression of interferon-stimulated genes (ISGs) in response to PVM infection in wild-type and IFNγ / mice. Differential expression of transcripts
encoding (A) Oas 1g (B) Oas2 (C) Oas3 and (D) Mx1 in PVM-infected wild-type and IFNγ/ mice. Mice were inoculated with 0.033 TCID50 units PVM strain J3666; n¼4–8
mice per time point. Shown are the means7SEM, **po0.01, ***po0.001, two-way ANOVA with Bonferroni’s multiple comparisons test.
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impact of exogenous mediator on cell survival, and even the
existence of receptors for IFNλ on human and/or mouse eosino-
phils remains to be determined.
It is interesting to reﬂect on these ﬁndings, given our under-
standing of patients devoid of interferon gamma receptor and thus
unable to respond to interferon gamma (Casanova and Abel, 2002).
These individuals are typically highly susceptible to infections with
intracellular pathogens (e.g., mycobacteria). Although respiratory virus
infection may be a comparatively limited concern in this patient
population (Dorman et al., 1999), our results here suggest that, in the
absence of IFNγ signaling, these individuals may experience heigh-
tened inﬂammatory response as part of the resolution of a respiratory
virus infection. While this response may not be overtly lethal, one – or
perhaps repeated episodes – of augmented post-viral inﬂammation
may have an unpredicted impact on the respiratory tract and its ability
to respond to incoming stimuli.
Conclusions
Immunoreactive IFNγ is produced in response to PVM infection
in mouse lung tissue. Although this has no discernible impact on
virus replication/clearance or on survival in response to acute
infection, we ﬁnd that PVM-infected IFNγ gene-deleted mice
express signiﬁcantly less IFNβ and likewise signiﬁcantly less
IFNλ2/3 than do their wild-type counterparts. IFNγ gene-deletion
results in more profound lung histopathology, which is detected
several days after peak virus recovery. Persistent elevations of
neutrophils and eosinophils are associated with differential
expression of chemoattractant and eosinophil-active cytokines,
and we show that IFNγ actively antagonizes eosinophil survival.
The impact of this ﬁnding on human health, notably the role of
heightened post-viral pulmonary inﬂammation observed among
those individuals devoid of IFNγ signaling might be explored.
Materials and methods
Mouse and virus stocks
Wild-type BALB/c and C57BL/6 mice were purchased from Division
of Cancer Therapeutics (DCT, National Cancer Institute, National
Institutes of Health, MD). IFNγ gene-deleted (IFNγ/) mice (Dalton
et al., 1993) on the BALB/c background are maintained by NIAID-
Taconic contract and IFNγR1 gene-deleted mice were from Jackson
Laboratories (Huang et al., 1993). CD2-IL5 transgenic mice (BALB/c
background; (Dent et al., 1990)) are maintained on site; 8–14 week old
mice were used in all experiments. IFNαβR/ mice (C57BL/6 back-
ground; (Muller et al., 1994)) were generated from heterozygotes as
described previously (Garvey et al., 2005); RNA samples generated
from PVM-infected (day 6 of infection) and uninfected mice for
microarray analysis described in the aforementioned manuscript were
utilized in this study. Mouse-passaged PVM strain J3666 is maintained
as an in vivo passaged stock; virus titer was determined both by
TCID50 (Percopo et al., 2011) and by a quantitative RT PCR method
(Gabryszewski et al., 2011). Mice received intranasal inocula (50 μL) of
virus while under isoﬂurane anesthesia and were likewise anesthe-
tized prior to sacriﬁce via cervical dislocation. All protocols were
evaluated and approved as per the National Institutes of Allergy and
Infectious Diseases Animal Study Protocol LAD 8E and carried out
in accordance with the Institute0s Animal Care and Use Committee
Guidelines.
Quantitative RT-PCR
Virus recovery was determined from cDNA generated from total
RNA from mouse lung tissue by a dual standard curve qRT-PCR
method that targets both the PVM small hydrophobic (SH) gene and
mouse GAPDH as previously described (Gabryszewski et al., 2011).
Detection of IFN-λ2/3, IFN-β, Mx1, Oas1g, Oas2 and Oas3 was carried
out using the 20 concentrated primer-probe set from ABI Assay by
Design (Mm04204156_gH; Mm00439546_s1; Mm00487796_m1;
Mm00726868_s1; Mm00460961_m1; Mm00460944_m1) used as
per manufacturer’s instructions (ABI, Columbia, MD). Relative expres-
sion was determined via normalization to mouse GAPDH and by
setting a single sample in the BALB/c wild-type day 0 set to 1.0.
Seroconversion
Anti-PVM IgG1 in mouse sera was detected by ELISA (Biotech
Trading Partners, catalog #SMART-M12, El Cerrito, CA).
Histopathology
Prior to excision of lungs from the chest cavity, excess blood
was removed by perfusion via the right ventricle with phosphate
buffered saline (PBS), and the lungs were inﬂated trans-tracheally
with 10% phosphate buffered formalin. The heart and the lungs
were removed and ﬁxed overnight in 10% phosphate buffered
formalin at 4 1C. Samples were parafﬁn-embedded, sectioned, and
stained with hematoxylin and eosin (Histoserv, Germantown, MD).
Fig. 4. IFNγ gene-deletion augments histopathology observed in response to non-
lethal PVM infection. (A) Lung histopathology was scored as described by Hardy
et al. (2009) as described in the Methods; shown are the means7SEM,
nnnpo0.001, two-way ANOVA with Bonferroni’s multiple comparisons test.
(B) Lung tissue from IFNγ/ mice on day 10 post-inoculation, in which lesions
are signiﬁcantly more profound and diffuse than those seen in (C) lung tissue from
wild-type mice (original magniﬁcations, 5 ); (D) likewise, more profound cellular
inﬁltration is observed in lung tissue from PVM-infected IFNγ/ mice when
compared to a corresponding section from (E) PVM-infected wild-type mice (H&E
staining, original magniﬁcations, 40 ), all mice inoculated with 0.033 TCID50 units
PVM strain J3666.
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The severity of pulmonary inﬂammation was scored according to a
histopathologic scheme similar to that described by Hardy et al.
(2009) as follows: a designation of severe (score 3) includes
peribronchiolar and bronchiolar inﬁltrates and pneumonia that
are diffuse and involving more than 50% of the lung tissue,
moderate (score 2) includes focal peribronchiolar and bronchiolar
inﬁltrates, and/or multifocal pneumonia present in 25 to 50% of
the lung, and mild (score 1) consists in a single site or several
localized lesions involving less than 25% of the lung; a fully normal
appearance was given a score of 0. A value was assigned to each
lung section and was used to calculate the total lung inﬂammation
score; 3 sections were scored from each mouse.
Bronchoalveolar lavage (BAL) and cell counts
Neutrophils and eosinophils were evaluated in BAL ﬂuid from
PVM-infected mice using modiﬁed Giemsa staining (Diff-Quik; Fisher
Scientiﬁc, Pittsburgh, PA). To prepare cells for staining, BAL ﬂuids
were subjected to centrifugation and re-suspended in 100 to 120 mL
PBS plus 0.1% bovine serum albumin (BSA). Cells (105 total) were
Fig. 5. Granulocytes are recruited to the airways and lung parenchyma of IFNγ gene-deleted mice. (A) Percent eosinophils and (B) percent neutrophils detected in the
bronchoalveolar lavage (BAL) ﬂuid of PVM-infected IFNγ / and wild-type mice; n¼ 6–10 mice per time point; in (A), examples of eosinophils in BAL ﬂuid (modiﬁed Giemsa
stain), as indicated by arrows in the inset. (C) Percent eosinophils (SiglecFþCD11c-) and (D) percent neutrophils (Gr1þ) recruited in the lung tissues of PVM-infected IFNγ
gene-deleted and wild-type mice; cells were evaluated by ﬂow cytometry, n¼7 mice pooled for each time point, data from 2 independent experiments. (E) Eosinophil
degranulation evaluated by detection of immunoreactive eosinophil peroxidase (EPX) in BAL ﬂuid, measured as eosinophil equivalents per mL (Ochkur et al. 2012). EPX
detected in BAL ﬂuid in wild-type and IFNγ/ mice are compared to results obtained from mice sensitized and challenged with Aspergillus fumigatus alone (Af), and mice
sensitized and challenged and subsequently infected with PVM (AfþPVM), the latter set of conditions shown to promote eosinophil degranulation [Percopo et al., 2014].
Mice were inoculated with 0.033 TCID50 units PVM strain J3666. Shown are the means7SEM, nnnpo0.001, two-way ANOVA with Bonferroni's multiple comparisons test.
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afﬁxed onto slides using a Shandon Cytospin apparatus (Thermo-
Electron, Pittsburgh, PA). Following staining and mounting of cells, 10
high-power ﬁelds were visually inspected by light microscopy.
Mouse eosinophil degranulation assay
This is ELISA for mouse eosinophil-speciﬁc eosinophil perox-
idase (EPX) performed as described in Ochkur et al. (2012).
Lung cell preparation and ﬂow cytometry
Lung tissue was harvested at the time points indicated and single
cell suspensions prepared as described in Garcia-Crespo et al. (2013).
Brieﬂy, lung cells (106) were ﬁrst stained with LIVE/DEADs Fixable
Yellow stain (Invitrogen, #L34959) in Hanks' buffered saline solution
(30 min, 4 1C). Cells were then stained in PBS with 0.1% BSA in the
presence of blocking anti-mouse CD16/CD32 (BD Biosciences, San Jose,
CA) for 60 min at 4 1C with two different sets of antibodies: (i) anti-
GR1-APC (BD Biosciences), anti-CD49b (DX5)-PE (BD Biosciences),
anti-CD3-Alexa-700 (eBioscience, San Diego, CA), anti-CD4-FITC
(eBioscience), anti-CD8-Pac-Blue (BioLegend, San Diego, CA), or (ii)
anti-GR1-V450, anti-CD11c-Alexa-488, anti-SiglecF-PE (BD Bios-
ciences), anti-MHC-II (I-A/I-E)-APC (eBioscience). Antibody-bound cells
were washed twice in PBS-BSA 0.1% and ﬁxed (4% paraformaldehyde/
PBS). Data were analyzed using an LSRII ﬂow cytometer (BD Bios-
ciences) in conjunction with algorithms in FlowJo 9.6. Neutrophils and
eosinophils were deﬁned as GR1highCD3-CD4-CD8-DX5- and Sigle-
cFþCD11c-GR1lowMHCII- respectively. A minimum of 250,000 events
was collected per sample; analyses are presented as percentage of
live cells.
Proinﬂammatory cytokine expression
ELISA analysis was performed to quantify immunoreactive
proteins using Quantikine and DuoSets kits from R&D Systems
(Minneapolis, MN) as per the manufacturer's instructions. Sensi-
tivities for the IL-5 and GM-CSF ELISAs are 7 and 5.8 pg/mL,
respectively. Data points generated using lung tissue homogenates
Fig. 6. Chemoattractant and eosinophil-active cytokines detected preferentially in lung tissue of PVM-infected IFNγ gene-deleted mice. (A) CCL11/eotaxin-1; (B) CXCL1 / KC;
(C) CCL3/MIP-1α; (C) IL-5; n¼6–10 mice per time point. Shown are the means7SEM, nnnpo0.001, nnpo0.01, two-way ANOVA with Bonferroni's multiple comparisons test.
Fig. 7. IFNγ antagonizes IL-5-mediated survival of mouse eosinophils. (A) Eosinophils
(t¼0 are day 12 cultures, 95–100% eosinophils) generated from bone marrow of (A)
wild-type mice (bmEos) and (B) IFNγR gene-deleted mice (IFNγR/ bmEos) with IL-5
alone (10 ng/mL), with IFNγ alone (100 ng/mL), or with IL-5 (10 ng/mL) and IFNγ (100
ng/mL) together; npo0.05. Shown are representatives of n¼3 experiments, each run
in triplicate.
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were normalized to total protein per sample, which was deter-
mined via BCA protein assay (Pierce, Rockford, IL).
Generation and survival of mouse bone marrow eosinophils (bmEos)
Bone-marrow derived eosinophils (bmEos) were generated
from wild-type (C57BL/6) and IFNγR gene-deleted mice as
described previously (Dyer et al., 2008). Cultures at day 12
contained 95–100% eosinophils, and became time point (t¼0)
for this study. From this point, cells were maintained in RPMI with
10% fetal calf serum and 10 mM glutamine with IL-5 (R&D
Systems, 10 ng/mL), IFN-γ (Peprotech, 100 ng/mL) or both cyto-
kines. Cell number and cell viability were monitored by hemocyt-
ometer counts with trypan blue staining in triplicate samples per
experiment.
Statistical analysis
Data were analyzed using two-way ANOVA with Bonferroni's
multiple comparison tests, as appropriate. All statistical tests were
included in the GraphPad Prism 6 software package (GraphPad
Software, La Jolla, CA). Grubbs' test was performed to detect
outliers. All bar graphs indicate the mean7SEM.
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